

15

5. The method as described in claim 1, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μ g/kg per day.

6. The method as described in claim 5, wherein the administration is at the amount of 0.1-10 μ g/kg per day.

7. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E_1 or a salt, ether, ester or amide thereof, to the subject.

8. The method as described in claim 7, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E_1 , or a pharmaceutically acceptable salt, ester or amide thereof.

9. The method for treating irritable bowel syndrome in a as described in claim 8, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ g/kg per day.

10. The method as described in claim 8, wherein the administration is in the amount of 0.1-10 μ g/kg per day.

11. The method as described in claim 7, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μ g/kg per day.

12. The method as described in claim 7, wherein the administration is at the amount of 0.1-10 μ g/kg per day.

13. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E_1 , or a salt, ether, ester or amide thereof, to the subject.

16

14. The method as described in claim 13, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E_1 , or a pharmaceutically acceptable salt, ester or amide thereof.

15. The method as described in claim 14, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ g/kg per day.

16. The method as described in claim 13, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ g/kg per day.

17. The method as described in claim 13, wherein the administration is in the amount of 0.1-10 μ g/kg per day.

18. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E_1 , or a salt, ether, ester or amide thereof, to the subject.

19. The method as described in claim 18, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E_1 , or a pharmaceutically acceptable salt, ester or amide thereof.

20. The method as described in claim 19, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ g/kg per day.

21. The method as described in claim 18, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μ g/kg per day.

22. The method as described in claim 18, wherein the administration is in the amount of 0.1-10 μ g/kg per day.

* * * * *